Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

被引:75
|
作者
Hamaoka, T. [2 ,3 ]
Costelloe, C. M. [4 ]
Madewell, J. E. [4 ]
Liu, P. [5 ]
Berry, D. A. [5 ]
Islam, R. [1 ]
Theriault, R. L. [1 ]
Hortobagyi, G. N. [1 ]
Ueno, N. T. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[3] St Lukes Int Hosp, Tokyo, Japan
[4] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
bone diseases; breast neoplasms; diagnostic imaging; response assessment; FDG-PET; THERAPY; SCAN; TOMOGRAPHY; CARCINOMA; DIAGNOSIS; ONCOLOGY;
D O I
10.1038/sj.bjc.6605546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to progression-free survival (PFS), overall survival (OS), and clinical response. METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS. RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified as nonresponders (P = 0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response assessment. CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis. British Journal of Cancer (2010) 102, 651-657. doi:10.1038/sj.bjc.6605546 www.bjcancer.com Published online 26 January 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:651 / 657
页数:7
相关论文
共 50 条
  • [1] Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
    T Hamaoka
    C M Costelloe
    J E Madewell
    P Liu
    D A Berry
    R Islam
    R L Theriault
    G N Hortobagyi
    N T Ueno
    British Journal of Cancer, 2010, 102 : 651 - 657
  • [2] Accurate tumor response assessment in bone-only metastatic breast cancer by comprehensive imaging and by new response criteria
    Hamaoka, T
    Costelloe, CM
    Madewell, JE
    Islam, R
    Rondon, G
    Ayers, GD
    Champlin, RE
    Berry, DA
    Hortobagyi, GN
    Ueno, NT
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S258 - S258
  • [3] Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria
    Trillet-Lenoir, V
    Freyer, G
    Kaemmerlen, P
    Fond, A
    Pellet, O
    Lombard-Bohas, C
    Gaudin, JL
    Lledo, G
    Mackiewicz, R
    Gouttebel, MC
    Moindrot, H
    Boyer, JD
    Chassignol, L
    Stremsdoerfer, N
    Desseigne, F
    Moreau, JM
    Hedelius, F
    Moraillon, A
    Chapuis, F
    Bleuse, JP
    Barbier, Y
    Heilmann, MO
    Valette, PJ
    BRITISH JOURNAL OF RADIOLOGY, 2002, 75 (899): : 903 - 908
  • [4] Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases
    Parkes, Amanda
    Warneke, Carla L.
    Clifton, Katherine
    Al-Awadhi, Aydah
    Oke, Oluchi
    Pestana, Roberto Carmagnani
    Alhalabi, Omar
    Litton, Jennifer K.
    Hortobagyi, Gabriel N.
    ONCOLOGIST, 2018, 23 (11): : 1282 - 1288
  • [5] Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes
    VanDalen, A
    Heering, KJ
    Barak, V
    Peretz, T
    Cremaschi, A
    Geroni, P
    Gion, M
    Saracchini, S
    Molina, R
    Namer, M
    Stieber, P
    Sturgeon, C
    Leonard, RCF
    Einarsson, R
    BREAST, 1996, 5 (02): : 82 - 88
  • [6] Complete response of bone-only metastatic breast cancer to skeletal:: Targeted radiotherapy with 166HOLMIUM-DOTMP.
    Booser, DJ
    Ueno, NT
    Rondon, G
    Williams, PA
    Wendt, R
    Hortobagyi, GN
    Podoloff, DA
    Champlin, RE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 21S - 21S
  • [7] Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer
    Curtit, E.
    Bazan, F.
    Chaigneau, L.
    Mouillet, G.
    Dobi, E.
    Mansi, L.
    Meneveau, N.
    Paillard, M-J.
    Meynard, G.
    Klajer, E.
    Villanueva, C.
    Montcuquet, P.
    Pivot, X.
    Cals, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] The evolving molecular characterisation, histological criteria and nomenclature of adenoid ameloblastoma as a World Health Organisation tumour type
    Odell, Edward W.
    Gomes, Carolina Cavalieri
    Thavaraj, Selvam
    HISTOPATHOLOGY, 2024,
  • [9] Real-world tumour response of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US clinical practices
    Brufsky, A.
    Liu, X.
    Li, B.
    Mcroy, L.
    Layman, R. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S79 - S79
  • [10] Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
    Marie, Lina
    Braik, Dina
    Abdel-Razeq, Nayef
    Abu-Fares, Hala
    Al-Thunaibat, Ahmad
    Abdel-Razeq, Hikmat
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2519 - 2531